PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
31.29%
Some net income increase while VET is negative at -13.11%. John Neff would see a short-term edge over the struggling competitor.
6.89%
Some D&A expansion while VET is negative at -5.88%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-0.42%
Negative yoy deferred tax while VET stands at 3.30%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
-400.77%
Both reduce yoy usage, with VET at -14.59%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both reduce yoy usage, with VET at -14.59%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-5042.90%
Negative yoy while VET is 165.33%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-29.47%
Both yoy CFO lines are negative, with VET at -3.92%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-25.08%
Negative yoy CapEx while VET is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
100.00%
Acquisition growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.03%
Both yoy lines negative, with VET at -54.32%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-72.10%
Both yoy lines negative, with VET at -54.32%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-3.15%
We cut debt repayment yoy while VET is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
132.61%
Lower share issuance yoy vs. VET's 29378.57%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
68.97%
Buyback growth of 68.97% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.